{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:51:51Z","timestamp":1792266711093,"version":"4.4.0"},"reference-count":4,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,12,20]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Early consolidation with BV improves 5-year PFS vs best supportive care and reduces the need for subsequent therapy. At 5-year follow-up, BV shows long-term tolerability, with peripheral neuropathy continuing to improve and\/or resolve.<\/jats:p>","DOI":"10.1182\/blood-2018-07-861641","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T17:58:45Z","timestamp":1538157525000},"page":"2639-2642","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":227,"title":["Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse"],"prefix":"10.1182","volume":"132","author":[{"given":"Craig H.","family":"Moskowitz","sequence":"first","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auayporn","family":"Nademanee","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Masszi","sequence":"additional","affiliation":[{"name":"3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Agura","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation, Baylor University Medical Center, Dallas, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Holowiecki","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation & Oncohematology, Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneer H.","family":"Abidi","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Program, Spectrum Health Cancer Center, Michigan State University, Grand Rapids, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy I.","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Stiff","sequence":"additional","affiliation":[{"name":"Cardinal Bernardain Cancer Center, Loyola University Medical Center, Maywood, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Viviani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Catal\u00e0 d\u2019Oncologia Hospitalet, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"McClendon","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc., Bothell, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Lee","sequence":"additional","affiliation":[{"name":"Takeda Oncology, Cambridge, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lisano","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc., Bothell, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sweetenham","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood and Marrow Transplant, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111913294540100_B1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","article-title":"Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant","volume":"54","author":"Arai","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"suppl 4","key":"2019111913294540100_B2","first-page":"120","article-title":"Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [abstract]","volume":"19","author":"Horning","year":"2008","journal-title":"Ann Oncol"},{"issue":"9980","key":"2019111913294540100_B3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"2019111913294540100_B4","unstructured":"European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man (appendix 1): methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/01\/WC500137126.pdf. Accessed 29 January 2018."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/25\/2639\/1468938\/blood861641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/25\/2639\/1468938\/blood861641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T19:38:31Z","timestamp":1574192311000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/25\/2639\/39577\/Fiveyear-PFS-from-the-AETHERA-trial-of-brentuximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,20]]},"references-count":4,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2018,12,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-07-861641","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,20]]}}}